SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity (Q44539666)

From Wikidata

Jump to navigation Jump to search

scientific article published in November 2003

Language	Label	Description	Also known as
English	SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity	scientific article published in November 2003

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity (English)

1 reference

Europe PubMed Central

4 December 2017

author name string

Ronan Depoortere

1

1 reference

Europe PubMed Central

4 December 2017

Denis Boulay

2

1 reference

Europe PubMed Central

4 December 2017

Ghislaine Perrault

3

1 reference

Europe PubMed Central

4 December 2017

Olivier Bergis

4

1 reference

Europe PubMed Central

4 December 2017

Michel Decobert

5

1 reference

Europe PubMed Central

4 December 2017

Dominique Françon

6

1 reference

Europe PubMed Central

4 December 2017

Mireille Jung

7

1 reference

Europe PubMed Central

4 December 2017

Jacques Simiand

8

1 reference

Europe PubMed Central

4 December 2017

Philippe Soubrié

9

1 reference

Europe PubMed Central

4 December 2017

Bernard Scatton

10

1 reference

Europe PubMed Central

4 December 2017

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

4 December 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

4 December 2017

28

1 reference

Europe PubMed Central

4 December 2017

11

1 reference

Europe PubMed Central

4 December 2017

1889-1902

1 reference

Europe PubMed Central

4 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300261

0 references

Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Do animal models of anxiety predict anxiolytic-like effects of antidepressants?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Schizophrenics kill themselves too: a review of risk factors for suicide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Barriers to progress--the impact of tolerability problems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

5-HT1A receptor agonists: recent developments and controversial issues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

The serotonin syndrome and its treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Working memory dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

5-HT2 antagonism and EPS benefits: is there a causal connection?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Behavioral aspects of serotonin-dopamine interaction in the monkey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

The role of serotonin in antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Risk factors for suicide in psychiatric patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Inhibition of REM sleep by fluoxetine, a specific inhibitor of serotonin uptake

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

21 January 2018

Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

7 January 2021

based on heuristic

inferred from DOI database lookup

On the mode of action of apomorphine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

7 January 2021

based on heuristic

inferred from DOI database lookup

5-HT1A receptors in lithium-induced conditioned taste aversion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300261

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1300261

0 references

1 reference

Europe PubMed Central

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44539666&oldid=2098894376"